Literature DB >> 11698667

Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

E J Goetzl1, J K Voice, S Shen, G Dorsam, Y Kong, K M West, C F Morrison, A J Harmar.   

Abstract

Vasoactive intestinal peptide (VIP) and its G protein-coupled receptors, VPAC(1)R and VPAC(2)R, are prominent in the immune system and regulate many aspects of T cell-dependent immunity. In mouse T cells, VPAC(1)R is expressed constitutively, whereas VPAC(2)R is induced by immune stimuli. VPAC(2)R-null (VPAC(2)R(-/-)) mice on a C57BL/6 background are shown here to have normal basic immune characteristics, including serum Ig concentrations, blood levels of all leukocytes, and spleen number of total T cells (CD3(+)) and T cells bearing CD4, CD8, and CD28. Hapten-evoked cutaneous delayed-type hypersensitivity (DTH) was significantly enhanced in VPAC(2)R-null mice compared with age- and sex-matched wild-type mice. In contrast, generation of IgE anti-hapten antibodies and active cutaneous anaphylaxis were > or =70% lower in VPAC(2)R-null mice than in wild-type controls. Cytokine production by splenic CD4(+) T cells, stimulated with adherent anti-CD3 plus anti-CD28 antibodies, revealed higher levels of IL-2 (mean = 3-fold) and IFN-gamma (mean = 3-fold), and lower levels of IL-4 (mean = one-fifth) in VPAC(2)R-null mice than wild-type controls. Loss of VIP-VPAC(2)R maintenance of the normal ratio of Th2/Th1 cytokines thus leads to a state of enhanced DTH and depressed immediate-type hypersensitivity, which may alter both host defense and susceptibility to immune-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698667      PMCID: PMC61131          DOI: 10.1073/pnas.241503798

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma.

Authors:  H B Kaltreider; S Ichikawa; P K Byrd; D A Ingram; J L Kishiyama; S P Sreedharan; M L Warnock; J M Beck; E J Goetzl
Journal:  Am J Respir Cell Mol Biol       Date:  1997-02       Impact factor: 6.914

2.  Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes.

Authors:  R Pankhaniya; N Jabrane-Ferrat; G O Gaufo; S P Sreedharan; P Dazin; J Kaye; E J Goetzl
Journal:  FASEB J       Date:  1998-01       Impact factor: 5.191

3.  Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.

Authors:  M Xia; S P Sreedharan; D R Bolin; G O Gaufo; E J Goetzl
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

4.  Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects.

Authors:  A Hernanz; E Tato; M De la Fuente; E de Miguel; F Arnalich
Journal:  J Neuroimmunol       Date:  1996-12       Impact factor: 3.478

5.  Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes.

Authors:  M Delgado; C Martinez; M C Johnson; R P Gomariz; D Ganea
Journal:  J Neuroimmunol       Date:  1996-08       Impact factor: 3.478

6.  Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane.

Authors:  M Xia; D Leppert; S L Hauser; S P Sreedharan; P J Nelson; A M Krensky; E J Goetzl
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

Review 7.  Matrix metalloproteinases in immunity.

Authors:  E J Goetzl; M J Banda; D Leppert
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

Review 8.  Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs.

Authors:  D Ganea
Journal:  Adv Neuroimmunol       Date:  1996

Review 9.  The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation.

Authors:  D L Bellinger; D Lorton; S Brouxhon; S Felten; D L Felten
Journal:  Adv Neuroimmunol       Date:  1996

10.  Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype.

Authors:  M Mackay; J Fantes; S Scherer; S Boyle; K West; L C Tsui; E Belloni; E Lutz; V Van Heyningen; A J Harmar
Journal:  Genomics       Date:  1996-11-01       Impact factor: 5.736

View more
  36 in total

1.  The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

Authors:  Amali E Samarasinghe; Scott A Hoselton; Jane M Schuh
Journal:  Peptides       Date:  2010-10-13       Impact factor: 3.750

Review 2.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

Review 3.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.

Authors:  Elena Gonzalez-Rey; Amelia Fernandez-Martin; Alejo Chorny; Javier Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 5.  Perspective is everything: an irreverent discussion of CNS-immune system interactions as viewed from different scientific traditions.

Authors:  Monica J Carson; David D Lo
Journal:  Brain Behav Immun       Date:  2007-01-17       Impact factor: 7.217

6.  A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

Authors:  Li Liu; Jui-Hung Yen; Doina Ganea
Journal:  Peptides       Date:  2007-03-31       Impact factor: 3.750

Review 7.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

Review 8.  Tissue-based class control: the other side of tolerance.

Authors:  Polly Matzinger; Tirumalai Kamala
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

Review 9.  Neuropeptides of the pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide/growth hormone-releasing hormone/secretin family in testis.

Authors:  Min Li; Akira Arimura
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

10.  Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system.

Authors:  Johannes Stegbauer; De-Hyung Lee; Silvia Seubert; Gisa Ellrichmann; Arndt Manzel; Heda Kvakan; Dominik N Muller; Stefanie Gaupp; Lars Christian Rump; Ralf Gold; Ralf A Linker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.